HomeCompareTYME vs MRK

TYME vs MRK: Dividend Comparison 2026

TYME yields 643.71% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TYME wins by $456723.63M in total portfolio value
10 years
TYME
TYME
● Live price
643.71%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$456723.69M
Annual income
$349,819,815,541.55
Full TYME calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — TYME vs MRK

📍 TYME pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTYMEMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TYME + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TYME pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TYME
Annual income on $10K today (after 15% tax)
$54,715.16/yr
After 10yr DRIP, annual income (after tax)
$297,346,843,210.32/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, TYME beats the other by $297,346,834,881.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TYME + MRK for your $10,000?

TYME: 50%MRK: 50%
100% MRK50/50100% TYME
Portfolio after 10yr
$228361.87M
Annual income
$174,909,912,669.85/yr
Blended yield
76.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TYME
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TYME buys
0
MRK buys
0
No recent congressional trades found for TYME or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTYMEMRK
Forward yield643.71%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$456723.69M$56.8K
Annual income after 10y$349,819,815,541.55$9,798.13
Total dividends collected$447927.36M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TYME vs MRK ($10,000, DRIP)

YearTYME PortfolioTYME Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$75,071$64,370.78$11,206$366.19+$63.9KTYME
2$531,949$451,622.81$12,650$502.35+$519.3KTYME
3$3,560,009$2,990,823.66$14,407$694.19+$3.55MTYME
4$22,515,533$18,706,324.17$16,585$967.82+$22.50MTYME
5$134,661,254$110,569,633.76$19,342$1,363.89+$134.64MTYME
6$762,121,745$618,034,202.42$22,913$1,947.19+$762.10MTYME
7$4,084,436,460$3,268,966,193.63$27,662$2,823.89+$4084.41MTYME
8$20,743,580,045$16,373,233,031.81$34,159$4,173.35+$20743.55MTYME
9$99,910,162,010$77,714,531,362.55$43,337$6,308.80+$99910.12MTYME
10$456,723,688,892$349,819,815,541.55$56,776$9,798.13+$456723.63MTYME

TYME vs MRK: Complete Analysis 2026

TYMEStock

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.

Full TYME Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TYME vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TYME vs SCHDTYME vs JEPITYME vs OTYME vs KOTYME vs MAINTYME vs JNJTYME vs ABBVTYME vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.